Vedran Pavlovic

589 total citations
21 papers, 322 citations indexed

About

Vedran Pavlovic is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Vedran Pavlovic has authored 21 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Epidemiology, 21 papers in Hepatology and 2 papers in Infectious Diseases. Recurrent topics in Vedran Pavlovic's work include Hepatitis B Virus Studies (21 papers), Hepatitis C virus research (20 papers) and Liver Disease Diagnosis and Treatment (17 papers). Vedran Pavlovic is often cited by papers focused on Hepatitis B Virus Studies (21 papers), Hepatitis C virus research (20 papers) and Liver Disease Diagnosis and Treatment (17 papers). Vedran Pavlovic collaborates with scholars based in United Kingdom, China and Germany. Vedran Pavlovic's co-authors include Cynthia Wat, Florian van Bömmel, Thomas Berg, Lei Yang, Danilo Deichsel, Stephan Böhm, Teerha Piratvisuth, Alena van Bömmel, Qing Xie and Robert J. de Knegt and has published in prestigious journals such as Hepatology, The Journal of Infectious Diseases and Journal of Hepatology.

In The Last Decade

Vedran Pavlovic

21 papers receiving 312 citations

Peers

Vedran Pavlovic

EPIDE

HEPAT

IMMUN

Miroslava Subic France

Hao Liao China

Simon B. Larsson Sweden

Dianhui Tan China

H.W. Reesink Netherlands

Taotao Yan China

Anika Wranke Germany

Qin-Yan Chen China

Maria Pfefferkorn Germany

Tony Carlsson Sweden

Miroslava Subic France

Vedran Pavlovic

294 ×1.0

EPIDE

264 ×0.9

HEPAT

27 ×0.9

23 ×1.1

IMMUN

31 ×1.7

Citations per year, relative to Vedran Pavlovic Vedran Pavlovic (= 1×) peers Miroslava Subic

Countries citing papers authored by Vedran Pavlovic

Since Specialization

Citations

This map shows the geographic impact of Vedran Pavlovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vedran Pavlovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vedran Pavlovic more than expected).

Fields of papers citing papers by Vedran Pavlovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vedran Pavlovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vedran Pavlovic. The network helps show where Vedran Pavlovic may publish in the future.

Co-authorship network of co-authors of Vedran Pavlovic

This figure shows the co-authorship network connecting the top 25 collaborators of Vedran Pavlovic. A scholar is included among the top collaborators of Vedran Pavlovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vedran Pavlovic. Vedran Pavlovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pfefferkorn, Maria, Jessica H. Brehm, Martin Brehm, et al.. (2025). Overrange dilution for improvement of hepatitis B core related antigen as a biomarker: protocol validation and examples for application. Virology. 609. 110576–110576. 1 indexed citations

Feld, Jordan J., Henry Lik‐Yuen Chan, Teerha Piratvisuth, et al.. (2025). Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology. 24(1). 121–130.e12. 1 indexed citations

Gane, Edward, Won Kim, Tien Huey Lim, et al.. (2023). First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection. Journal of Hepatology. 79(5). 1139–1149. 25 indexed citations

Cheung, TT, Andrea O. Y. Luk, Yuchen Zhang, et al.. (2023). A single ascending dose study of single‐stranded oligodeoxyribonucleotide RO7062931 in Chinese healthy volunteers. Clinical and Translational Science. 16(7). 1272–1282. 1 indexed citations

Sonneveld, Milan J., Bettina E. Hansen, Willem Pieter Brouwer, et al.. (2020). Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. The Journal of Infectious Diseases. 225(11). 1967–1973. 11 indexed citations

Pfefferkorn, Maria, Stephan Böhm, Danilo Deichsel, et al.. (2020). Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. Journal of Hepatology. 74(2). 283–292. 43 indexed citations

Sonneveld, Milan J., Willem Pieter Brouwer, Bettina E. Hansen, et al.. (2020). Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Alimentary Pharmacology & Therapeutics. 52(8). 1399–1406. 20 indexed citations

Yuen, Man‐Fung, Edward Gane, Dong Joon Kim, et al.. (2020). RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy. Journal of Hepatology. 73. S51–S51. 7 indexed citations

Sonneveld, Milan J., Willem Pieter Brouwer, Henry LY Chan, et al.. (2019). Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. The Lancet. Gastroenterology & hepatology. 4(7). 538–544. 47 indexed citations

10.

Bremer, Corinna M., Katrin Schröder, Steffen B. Wiegand, et al.. (2019). Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a. Liver International. 40(2). 324–332. 12 indexed citations

11.

Wei, Lai, Vedran Pavlovic, Aruna T. Bansal, et al.. (2019). Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. Journal of Viral Hepatitis. 26(9). 1040–1049. 2 indexed citations

12.

Chan, Henry Lik‐Yuen, Diethelm Messinger, George Papatheodoridis, et al.. (2018). A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 48(5). 547–555. 22 indexed citations

13.

Wirth, Stefan, Hongfei Zhang, Winita Hardikar, et al.. (2018). Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study. Hepatology. 68(5). 1681–1694. 35 indexed citations

14.

Pavlovic, Vedran, Lei Yang, Henry Lik‐Yuen Chan, et al.. (2018). Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. Antiviral Therapy. 24(2). 133–140. 8 indexed citations

15.

Lampertico, Pietro, Diethelm Messinger, Markus Cornberg, et al.. (2016). A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B. Journal of Hepatology. 64(2). S599–S600. 3 indexed citations

16.

Chan, Henry Lik‐Yuen, Diethelm Messinger, George Papatheodoridis, et al.. (2016). A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection. Journal of Hepatology. 64(2). S589–S590. 1 indexed citations

17.

Bremer, Corinna M., Birgit Bremer, Michael P. Manns, et al.. (2015). P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients. Journal of Hepatology. 62. S524–S525. 5 indexed citations

18.

Bömmel, Florian van, Alena van Bömmel, Hua He, et al.. (2015). P0643 : Serum HBV RNA is an early predictor of HBeAg seroconversion in patients with chronic hepatitis B (CHB) treated with Peg-Interferon alpha-2A (40kD). Journal of Hepatology. 62. S560–S560. 1 indexed citations

19.

Schwarz, Kathleen B., Jean P. Molleston, Maureen M. Jonas, et al.. (2015). Durability of Response in Children Treated With Pegylated Interferon alfa‐2a ± Ribavirin for Chronic Hepatitis C. Journal of Pediatric Gastroenterology and Nutrition. 62(1). 93–96. 14 indexed citations

20.

Jonas, Maureen M., Kathleen B. Schwarz, Regino P. González‐Peralta, et al.. (2014). Long-Term Growth Outcomes in Children Treated for Chronic Hepatitis C. The Journal of Pediatrics. 165(6). 1252–1254. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact